Chugai Pharmaceutical Co Ltd (4519.T)
30 Sep 2016
Latest Key Developments (Source: Significant Developments)
Chugai Pharmaceutical Co Ltd:To issue a year-end dividend of 26 yen per share, for the FY ending Dec. 2014.Dividend issued to shareholders of record as of Dec. 31.Dividend payment date March 27.Says the dividend amount is above the latest forecast of 23 yen per share disclosed on Jan. 30, 2014. Full Article
Chugai Pharmaceutical Co Ltd:Received judgment of lawsuit from Tokyo District Court on Dec. 24.Filed a lawsuit against Iwaki Seiyaku Co.,Ltd, DKSH Japan K.K., POLA-Pharma and TAKATA SEIYAKU Co., Ltd. due to infringement of Chugai Pharmaceutical Co Ltd's patent of keratosis treatment agent (patent No. 3310301) of the four companies on Feb. 19, 2013.Judgment says provisional disposition instruction of import and sale injunction of the keratosis treatment agent for the four companies. Full Article
Chiome Bioscience Inc announces joint research contract period extension with Chugai Pharmaceutical Co., Ltd.
Chiome Bioscience Inc:Announces joint research contract period extension to Dec. 31, 2015 with Chugai Pharmaceutical Co., Ltd. Full Article
Chugai Pharmaceutical Co Ltd completes phase I results of Chugai’s Bispecific Antibody "ACE910" released at the American society of hematology meeting
Chugai Pharmaceutical Co Ltd:Announces the phase I clinical data of anti-factor IXa x anti-factor X humanized bispecific antibody "ACE910," currently being developed for the indication of hemophilia A was presented at the 56th American Society of Hematology Annual Meeting on Dec. 8.Announces positive trial result on safety and efficacy of the ACE910. Full Article
* Chugai will continue to be responsible for product manufacturing and supply of Nemolizumab.